147 related articles for article (PubMed ID: 21529077)
1. Dynamic fluorescence imaging for multiparametric measurement of tumor vasculature.
Choi M; Choi K; Ryu SW; Lee J; Choi C
J Biomed Opt; 2011 Apr; 16(4):046008. PubMed ID: 21529077
[TBL] [Abstract][Full Text] [Related]
2. Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents.
Zhang Q; Bindokas V; Shen J; Fan H; Hoffman RM; Xing HR
Mol Cancer Ther; 2011 Jul; 10(7):1173-84. PubMed ID: 21586628
[TBL] [Abstract][Full Text] [Related]
3. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
4. In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice.
Ullrich RT; Jikeli JF; Diedenhofen M; Böhm-Sturm P; Unruh M; Vollmar S; Hoehn M
PLoS One; 2011 May; 6(5):e19592. PubMed ID: 21573168
[TBL] [Abstract][Full Text] [Related]
5. Imaging in the age of molecular medicine: monitoring of anti-angiogenic treatments.
Lederle W; Palmowski M; Kiessling F
Curr Pharm Biotechnol; 2012 Mar; 13(4):595-608. PubMed ID: 22214504
[TBL] [Abstract][Full Text] [Related]
6. Developing DCE-CT to quantify intra-tumor heterogeneity in breast tumors with differing angiogenic phenotype.
Cao M; Liang Y; Shen C; Miller KD; Stantz KM
IEEE Trans Med Imaging; 2009 Jun; 28(6):861-71. PubMed ID: 19150783
[TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density.
Wild R; Ramakrishnan S; Sedgewick J; Griffioen AW
Microvasc Res; 2000 May; 59(3):368-76. PubMed ID: 10792968
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric evaluation of hindlimb ischemia using time-series indocyanine green fluorescence imaging.
Guang H; Cai C; Zuo S; Cai W; Zhang J; Luo J
J Biophotonics; 2017 Mar; 10(3):456-464. PubMed ID: 27135903
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoid-mediated effects on angiogenesis in solid tumors.
Martens B; Drebert Z
J Steroid Biochem Mol Biol; 2019 Apr; 188():147-155. PubMed ID: 30654109
[TBL] [Abstract][Full Text] [Related]
10. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.
Jain RK; Tong RT; Munn LL
Cancer Res; 2007 Mar; 67(6):2729-35. PubMed ID: 17363594
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive imaging for studying anti-angiogenic therapy effects.
Ehling J; Lammers T; Kiessling F
Thromb Haemost; 2013 Mar; 109(3):375-90. PubMed ID: 23407722
[TBL] [Abstract][Full Text] [Related]
12. Mammalian tumor xenografts induce neovascularization in zebrafish embryos.
Nicoli S; Ribatti D; Cotelli F; Presta M
Cancer Res; 2007 Apr; 67(7):2927-31. PubMed ID: 17409396
[TBL] [Abstract][Full Text] [Related]
13. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
14. Advanced Chemoembolization by Anti-angiogenic Calcium-Phosphate Ceramic Microspheres Targeting the Vascular Heterogeneity of Cancer Xenografts.
Emoto M; Yoshihisa H; Yano K; Choijamts B; Tsugu H; Tachibana K; Aizawa M
Anticancer Res; 2015 Sep; 35(9):4757-64. PubMed ID: 26254366
[TBL] [Abstract][Full Text] [Related]
15. Tumor-initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs.
Benayoun L; Gingis-Velitski S; Voloshin T; Segal E; Segev R; Munster M; Bril R; Satchi-Fainaro R; Scherer SJ; Shaked Y
Stem Cells; 2012 Sep; 30(9):1831-41. PubMed ID: 22782858
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis inhibitors. Drug selectivity and target specificity.
Kesisis G; Broxterman H; Giaccone G
Curr Pharm Des; 2007; 13(27):2795-809. PubMed ID: 17897024
[TBL] [Abstract][Full Text] [Related]
17. Real-time visualization and characterization of tumor angiogenesis and vascular response to anticancer therapies.
Xing HR; Zhang Q
Methods Mol Biol; 2012; 872():115-27. PubMed ID: 22700407
[TBL] [Abstract][Full Text] [Related]
18. Imaging tumor angiogenesis.
Red-Horse K; Ferrara N
J Clin Invest; 2006 Oct; 116(10):2585-7. PubMed ID: 17016553
[TBL] [Abstract][Full Text] [Related]
19. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
